Krystal Biotech, Inc. (KRYS)
$331.61+1.32%Close
SELLBEAR · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9.8B
- Beta
- 0.50
- P/E (TTM)
- 39.52
- Short % float
- 14.84%
- Days to cover
- 11.2
- SI change
- +9.9%
- 1W
- +2.89%
- 1M
- -4.03%
- vs SPY 1W
- +1.73%
- vs SPY 1M
- -7.03%
Industry peers
FMP comparable companies · ranked by market cap
- PCVXBUYVaxcyte, Inc.$10.7BRECOVERYQ 26$73.82+9.78%
- PTGXSELLProtagonist Therapeutics, Inc.$9.0BRECOVERYQ 32$140.63+2.73%
- ARWRSELLArrowhead Pharmaceuticals, Inc.$8.8BCRISISQ 12$62.35+3.31%
- TGTXSELLTG Therapeutics, Inc.$8.3BBEARQ 11$53.91+3.81%
- MTSRMetsera, Inc.$7.4B$70.50
- ALKSSELLAlkermes plc$7.2BRECOVERYQ 6$42.76+1.25%
- ACLXArcellx, Inc.$6.7B$115.07
- TFXSELLTeleflex Incorporated$5.5BBEARQ 11$125.24+0.75%
- CRSPSELLCRISPR Therapeutics AG$5.5BBEARQ 20$57.34+5.85%
- PTCTSELLPTC Therapeutics, Inc.$5.3BRECOVERYQ 18$63.65+3.42%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on KRYS?
- LOPJLB’s latest quantitative signal on Krystal Biotech, Inc. (KRYS) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is KRYS in?
- Krystal Biotech, Inc. (KRYS) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Krystal Biotech, Inc. (KRYS) do?
- Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several …